Abiopharma

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Gain Therapeutics Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Avient To Hold Fourth Quarter 2025 Conference Call

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

GSK plc (GLAXF) Files Form 6-K

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC